Theragenics Corporation (NYSE: TGX) expects to release first quarter 2010 consolidated financial results before the market opens on May 4, 2010. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.
To participate in the call, dial 800-538-9844 or 706-634-7274 and provide the conference ID 70714849. This call is also being webcast and can be accessed via Theragenics' website, www.theragenics.com. A replay will be available on the website for one month. A phone replay will be available until Midnight, May 11, by dialing 800-642-1687 or 706-645-9291 and entering the conference ID 70714849.
Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The surgical products segment serves a number of markets and applications, including, among others, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics' brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer.
Contacts:
Theragenics Corporation
Frank J. Tarallo, CFO & Treasurer
Lisa
Rassel, Manager, Investor Relations
770-271-0233, 800-998-8479
www.theragenics.com
